Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
The multidisciplinary meeting: An indispensable aid to communication between different specialities
Ruhstaller T, Roe H, Thürlimann B, Nicoll J. The multidisciplinary meeting: An indispensable aid to communication between different specialities. EJC 2006; 42:2459-62.
01.10.2006The multidisciplinary meeting: An indispensable aid to communication between different specialities
01.10.2006EJC 2006; 42:2459-62
Ruhstaller Thomas, Roe Helen, Thürlimann Beat, Nicoll Jonathan J
Development of a gel-simulation model and generation of standard tables for the complete extirpation of benign breast lesions with vacuum assisted biopsy under ultrasound guidance
Krainick-Strobel U, Wallwiener D, Hoffmann J, Meyberg-Solomayer G, Doser M, Hierlemann H, Huober J, Fehm T, Gruber I, Krämer B, Gall C, Huber B, Majer I, Hahn M. Development of a gel-simulation model and generation of standard tables for the complete extirpation of benign breast lesions with vacuum assisted biopsy under ultrasound guidance. Ultrasound in medicine & biology 2006; 32:1539-44.
01.10.2006Development of a gel-simulation model and generation of standard tables for the complete extirpation of benign breast lesions with vacuum assisted biopsy under ultrasound guidance
01.10.2006Ultrasound in medicine & biology 2006; 32:1539-44
Krainick-Strobel Ute, Wallwiener Diethelm, Hoffmann Jürgen, Meyberg-Solomayer Gabriele, Doser Michael, Hierlemann Helmut, Huober Jens, Fehm Tanja, Gruber Ines, Krämer Bernhard, Gall Christian, Huber Birte, Majer Ina, Hahn Markus
Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL)
Betticher D, Cerny T, Maibach R, Cina S, Cogliatti S, Kovascovics T, von Rohr A, Beck J, Aulitzky W, Kaiser U, Dyer M, Kaufmann M, Radford J, Martinelli G, Linch D. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006; 17:1546-52.
01.10.2006Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL)
01.10.2006Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006; 17:1546-52
Betticher D C, Cerny Thomas, Maibach R, Cina S, Cogliatti S B, Kovascovics T, von Rohr A, Beck J, Aulitzky W E, Kaiser U, Dyer M J S, Kaufmann M, Radford J A, Martinelli G, Linch D C
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03
Herrlinger U, Reifenberger G, Bamberg M, Sommer C, Tan T, Meyermann R, Wick W, Hundsberger T, Steinbach J, Kortmann R, Blaschke B, Loeser S, Koch D, Rieger J, Weller M. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006; 24:4412-7.
20.09.2006Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03
20.09.2006Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006; 24:4412-7
Herrlinger Ulrich, Reifenberger Guido, Bamberg Michael, Sommer Clemens, Tan Ta-Chih, Meyermann Richard, Wick Wolfgang, Hundsberger Thomas, Steinbach Joachim P, Kortmann Rolf-Dieter, Blaschke Britta, Loeser Simon, Koch Dorothee, Rieger Johannes, Weller Michael
FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248)
Schittenhelm M, Cherrington J, O'Farrell A, Braziel R, Bainbridge T, Griffith D, Town A, Haley A, McGreevey L, Tyner J, Yee K, Heinrich M. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia 2006; 20:2008-14.
14.09.2006FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248)
14.09.2006Leukemia 2006; 20:2008-14
Schittenhelm Marcus, Cherrington J M, O'Farrell A-M, Braziel R M, Bainbridge T, Griffith D J, Town A, Haley A D, McGreevey L, Tyner J W, Yee K W H, Heinrich M C
Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate
Brouwers E, Tibben M, Rosing H, Hillebrand M, Jörger M, Schellens J, Beijnen J. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. Journal of mass spectrometry : JMS 2006; 41:1186-94.
01.09.2006Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate
01.09.2006Journal of mass spectrometry : JMS 2006; 41:1186-94
Brouwers E E M, Tibben M M, Rosing H, Hillebrand M J X, Jörger Markus, Schellens J H M, Beijnen J H
Trends in the epidemiology of total shoulder arthroplasty in the United States from 1990-2000
Jain N, Higgins L, Gueller U, Pietrobon R, Katz J. Trends in the epidemiology of total shoulder arthroplasty in the United States from 1990-2000. Arthritis Rheum 2006; 55:591-7.
15.08.2006Trends in the epidemiology of total shoulder arthroplasty in the United States from 1990-2000
15.08.2006Arthritis Rheum 2006; 55:591-7
Jain Nitin B, Higgins Laurence D, Gueller Ulrich, Pietrobon Ricardo, Katz Jeffrey N
[Extramedullary myeloma manifestations: imaging findings]
Horger M, Brodoefel H, Driessen C. [Extramedullary myeloma manifestations: imaging findings]. RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 2006; 178:747-51.
01.08.2006[Extramedullary myeloma manifestations: imaging findings]
01.08.2006RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 2006; 178:747-51
Horger M, Brodoefel H, Driessen Christoph
Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy
Decker M, Rothermundt C, Holländer G, Tichelli A, Rochlitz C. Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. The lancet oncology 2006; 7:693-4.
01.08.2006Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy
01.08.2006The lancet oncology 2006; 7:693-4
Decker Michael, Rothermundt Christian, Holländer Georg, Tichelli André, Rochlitz Christoph
Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network
Omlin A, Goldberg H, Scandolaro L, Gastelblum P, Ozsahin M, Dohr D, Christie D, Oppitz U, Abacioglu U, Morgan D, Gutierrez Miguelez C, Amichetti M, Azria D, Cole B, Fourneret P, Poortmans P, Naehrig D, Miller R, Krengli M, Gruber G. Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. The lancet oncology 2006; 7:652-6.
01.08.2006Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network
01.08.2006The lancet oncology 2006; 7:652-6
Omlin Aurelius, Goldberg Hadassah, Scandolaro Luciano, Gastelblum Pauline, Ozsahin Mahmut, Dohr Dagmar, Christie David, Oppitz Ulrich, Abacioglu Ufuk, Morgan David, Gutierrez Miguelez Cristina, Amichetti Maurizio, Azria David, Cole Bernard F, Fourneret Philippe, Poortmans Philip, Naehrig Diana, Miller Robert C, Krengli Marco, Gruber Guenther
Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients
Jörger M, Huitema A, Boogerd W, van der Sande J, Schellens J, Beijnen J. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. Basic & clinical pharmacology & toxicology 2006; 99:133-40.
01.08.2006Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients
01.08.2006Basic & clinical pharmacology & toxicology 2006; 99:133-40
Jörger Markus, Huitema A D R, Boogerd W, van der Sande J J, Schellens J H M, Beijnen J H
Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers
Jörger M, Bosch T, Doodeman V, Beijnen J, Smits P, Schellens J. Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. European journal of clinical pharmacology 2006; 62:681-4.
01.08.2006Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers
01.08.2006European journal of clinical pharmacology 2006; 62:681-4
Jörger Markus, Bosch T M, Doodeman V D, Beijnen J H, Smits P H M, Schellens J H M
Cell-cycle progression and response of germ cell tumors to cisplatin in vitro
Mueller S, Schittenhelm M, Honecker F, Malenke E, Lauber K, Wesselborg S, Hartmann J, Bokemeyer C, Mayer F. Cell-cycle progression and response of germ cell tumors to cisplatin in vitro. Int J Oncol 2006; 29:471-9.
01.08.2006Cell-cycle progression and response of germ cell tumors to cisplatin in vitro
01.08.2006Int J Oncol 2006; 29:471-9
Mueller Sandra, Schittenhelm Marcus, Honecker Friedemann, Malenke Elke, Lauber Kirsten, Wesselborg Sebastian, Hartmann Joerg T, Bokemeyer Carsten, Mayer Frank
Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes
Sparidans R, Bosch T, Jörger M, Schellens J, Beijnen J. Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006; 839:45-53.
24.07.2006Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes
24.07.2006Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006; 839:45-53
Sparidans Rolf W, Bosch T M, Jörger Markus, Schellens Jan H M, Beijnen Jos H
Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group
Cannabis-In-Cachexia-Study-Group, Reif M, Schnelle M, Ko Y, Meissner W, Ruhstaller T, Ernst G, Possinger K, Luftner D, Strasser F, Cerny T. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006; 24:3394-400.
20.07.2006Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group
20.07.2006Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006; 24:3394-400
Cannabis-In-Cachexia-Study-Group, Reif Marcus, Schnelle Martin, Ko You-Dschun, Meissner Winfried, Ruhstaller Thomas, Ernst Gernot, Possinger Kurt, Luftner Diana, Strasser Florian, Cerny Thomas
Multicentric breast cancer: a new indication for sentinel node biopsy--a multi-institutional validation study
Knauer M, Konstantiniuk P, Haid A, Wenzl E, Riegler-Keil M, Pöstlberger S, Reitsamer R, Schrenk P. Multicentric breast cancer: a new indication for sentinel node biopsy--a multi-institutional validation study. J Clin Oncol 2006; 24:3374-80.
20.07.2006Multicentric breast cancer: a new indication for sentinel node biopsy--a multi-institutional validation study
20.07.2006J Clin Oncol 2006; 24:3374-80
Knauer Michael, Konstantiniuk Peter, Haid Anton, Wenzl Etienne, Riegler-Keil Michaela, Pöstlberger Sabine, Reitsamer Roland, Schrenk Peter
Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients
Jörger M, Huitema A, van den Bongard H, Baas P, Schornagel J, Schellens J, Beijnen J. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. British journal of clinical pharmacology 2006; 62:71-80.
01.07.2006Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients
01.07.2006British journal of clinical pharmacology 2006; 62:71-80
Jörger Markus, Huitema A D R, van den Bongard H J G D, Baas P, Schornagel J H, Schellens J H M, Beijnen J H
Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients
Solomayer E, Huober J, Wallwiener D, Neubauer H, Vogel U, Krämer B, Bachmann R, Pergola-Becker G, Becker S, Fehm T. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast cancer research and treatment 2006; 98:179-84.
01.07.2006Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients
01.07.2006Breast cancer research and treatment 2006; 98:179-84
Solomayer Erich F, Huober Jens, Wallwiener Diethelm, Neubauer Hans, Vogel Ulrich, Krämer Bernhard, Bachmann Robert, Pergola-Becker Graziella, Becker Sven, Fehm Tanja N
Randomized controlled trials do not reflect reality: real-world analyses are critical for treatment guidelines!
Grapow M, von Wattenwyl R, Gueller U, Beyersdorf F, Zerkowski H. Randomized controlled trials do not reflect reality: real-world analyses are critical for treatment guidelines!. J Thorac Cardiovasc Surg 2006; 132:5-7.
01.07.2006Randomized controlled trials do not reflect reality: real-world analyses are critical for treatment guidelines!
01.07.2006J Thorac Cardiovasc Surg 2006; 132:5-7
Grapow Martin T R, von Wattenwyl Robert, Gueller Ulrich, Beyersdorf Friedhelm, Zerkowski Hans-Reinhard
Medium-term follow-up data after sentinel node biopsy alone for breast cancer
Haid A, Knauer M, Köberle-Wührer R, Ammann K, Koller L, Eiter H, Lang A, Wenzl E. Medium-term follow-up data after sentinel node biopsy alone for breast cancer. Eur J Surg Oncol 2006; 32:1180-5.
05.06.2006Medium-term follow-up data after sentinel node biopsy alone for breast cancer
05.06.2006Eur J Surg Oncol 2006; 32:1180-5
Haid A, Knauer Michael, Köberle-Wührer R, Ammann K, Koller L, Eiter H, Lang A, Wenzl E